RHBDF2

Across TCGA pan-cancer cohorts, RHBDF2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RHBDF2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RHBDF2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RHBDF2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where RHBDF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.718	0.947	<.001	104	view →
PDAC	DFS	Quartile	II,III,IV	0.215	0.507	<.001	85	view →
HNSC	OS	Median	II,III,IV	0.838	0.608	.002	52	view →
LUAD	DFS	Median	II,III,IV	0.719	0.311	.010	7	view →
UCEC	DFS	Median	III,IV	0.904	0.445	.037	4	view →
LSCC	DFS	Median	II,III,IV	0.482	0.928	.019	3	view →
GBM	OS	Quartile	All	0.281	0.604	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RHBDF2–CCRCC (OS)

Open the CCRCC breakdown →